DTaP-IPV-HepB vaccine
Combination vaccine
DTaP-IPV-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated polio vaccine or DTaP-IPV-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B.
A branded formulation is marketed in the U.S. as Pediarix by GlaxoSmithKline.
DTaP
The DTaP portion of the vaccine protects against three bacterial infections: diphtheria, tetanus, and pertussis (whooping cough). Diphtheria is a bacterium that causes problems with breathing, heart failure, paralysis, and in some cases death. It is spread via human to human interaction. Tetanus is spread via open cuts or wounds in the body. It can lead to stiffening of the muscles, which can result in difficulties breathing. Pertussis, also known as whooping cough, is the is "aP" portion of the DTaP vaccine. Like diphtheria, it is spread via human to human interaction. With the vaccine, children can build up a supply of antibodies that prevent infection. In general, the DTaP vaccine is only administered to children ages 7 and younger.
The public source identifies “DTaP-IPV-HepB vaccine” as combination vaccine. This brief keeps that definition visible, then builds a research path around DTaP-IPV-HepB, vaccine and Combination.
Why this record matters
A short description can identify a subject without explaining its stakes. For “DTaP-IPV-HepB vaccine”, the useful work is to connect “combination vaccine” to the records capable of establishing context and consequence.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated May 22, 2026. The linked authority identifier is Q55608806. None of the 0 selected statements returned an explicit reference.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “DTaP-IPV-HepB vaccine”, its source revision and the description used here.
- Expand the search: follow DTaP-IPV-HepB vaccine primary sources, DTaP-IPV-HepB vaccine archive and DTaP-IPV-HepB research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “DTaP-IPV-HepB vaccine”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “DTaP-IPV-HepB vaccine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.